Rapamycin

A rheostat for CD8+ T-cell-mediated tumor therapy

Rupesh K. Srivastava, Adam Utley, Protul A. Shrikant

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.

Original languageEnglish (US)
Pages (from-to)1189-1190
Number of pages2
JournalOncoImmunology
Volume1
Issue number7
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Sirolimus
T-Lymphocytes
Immunity
Neoplasms
Viral Vaccines
Therapeutics
Cell Differentiation
Vaccination
Vaccines

Keywords

  • Cancer
  • Memory CD8 T cells
  • mTOR
  • Rapamycin
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Srivastava, R. K., Utley, A., & Shrikant, P. A. (2012). Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy. OncoImmunology, 1(7), 1189-1190. https://doi.org/10.4161/onci.20663

Rapamycin : A rheostat for CD8+ T-cell-mediated tumor therapy. / Srivastava, Rupesh K.; Utley, Adam; Shrikant, Protul A.

In: OncoImmunology, Vol. 1, No. 7, 2012, p. 1189-1190.

Research output: Contribution to journalArticle

Srivastava, RK, Utley, A & Shrikant, PA 2012, 'Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy', OncoImmunology, vol. 1, no. 7, pp. 1189-1190. https://doi.org/10.4161/onci.20663
Srivastava, Rupesh K. ; Utley, Adam ; Shrikant, Protul A. / Rapamycin : A rheostat for CD8+ T-cell-mediated tumor therapy. In: OncoImmunology. 2012 ; Vol. 1, No. 7. pp. 1189-1190.
@article{24fd6bc6c45540da88899ebbc1063571,
title = "Rapamycin: A rheostat for CD8+ T-cell-mediated tumor therapy",
abstract = "Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.",
keywords = "Cancer, Memory CD8 T cells, mTOR, Rapamycin, Vaccine",
author = "Srivastava, {Rupesh K.} and Adam Utley and Shrikant, {Protul A.}",
year = "2012",
doi = "10.4161/onci.20663",
language = "English (US)",
volume = "1",
pages = "1189--1190",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Rapamycin

T2 - A rheostat for CD8+ T-cell-mediated tumor therapy

AU - Srivastava, Rupesh K.

AU - Utley, Adam

AU - Shrikant, Protul A.

PY - 2012

Y1 - 2012

N2 - Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.

AB - Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.

KW - Cancer

KW - Memory CD8 T cells

KW - mTOR

KW - Rapamycin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84877057592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877057592&partnerID=8YFLogxK

U2 - 10.4161/onci.20663

DO - 10.4161/onci.20663

M3 - Article

VL - 1

SP - 1189

EP - 1190

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 7

ER -